ArticleBMC genomics2025
The comparative genomic analysis provides insight into the divergent inhibitory activity metabolites in pathogen-driven three Pseudomonas palleroniana strains against primary pathogens of Pseudostellaria heterophylla.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances inMolecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pseudostellaria heterophylla (Miq.) Pax ex Pax et Hoffm. is a member of the Caryophyllaceae family, in which dried tuberous root is the well-known traditional Chinese medicine (TCM) and a widespread food ingredient in Asia. In recent years, the large-scale cultivation of P. heterophylla has led to frequent infectious diseases caused by multiple pathogens. However, efficient and safe approaches for preventing and managing P. heterophylla diseases have become urgent for this high-quality industrial development. Herein, a culturable microbiome of diseased P. heterophylla rhizosphere soil was constructed, and the broad-spectrum antifungal activity of Pseudomonas was screened. Three P. palleroniana strains, B-BH16-1, B-JK4-1, and HP-YBB-1B, were isolated and identified with vigorous antifungal activity by confrontation method. We employed the PacBio RS II single-molecule real-time (SMRT) sequencing and Illumina sequencing methods to obtain the genome of these three isolates. Phylogenetic, synteny, and ANI analysis showed that the lineage between strain B-JK4-1 with B-BH16-1 or HY-YBB-1B was closer than that between strain B-BH16-1 with HP-YBB-1B. The comparative genome of strains B-BH16-1, B-JK4-1, and HP-YBB-1B showed marked differences in secondary metabolite biosynthesis genes among these three P. palleroniana strains. Strain B-BH16-1, B-JK4-1, and HP-YBB-1 produced tolaasin I/tolaasin F (23 genes), sessilin A (37 genes), and putisolvin (39 genes), respectively. CAZyme analysis showed that 126, 129, and 127 CAZymes were identified in strains B-BH16-1, B-JK4-1, and HP-YBB-1B genomes, which genes in auxiliary activities (AA), carbohydrate esterases (CE), and glycosyl transferases (GT) categories were different among these three strains. These results provide new insights into the divergent antifungal metabolites in pathogen-driven three P. palleroniana strains against primary pathogens of Pseudostellaria heterophylla.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.